Clinical Trial Update: Addition of Enzalutamide to First Line Docetaxel for Castration Resistant Prostate Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the addition of enzalutamide to first-line docetaxel in castration-resistant prostate cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Taxotere (docetaxel)
• Xtandi (enzalutamide)

Snippet

Sponsor: Santa Chiara Hospital | Conditions: Prostatic Neoplasms | Phase 2 | Status: COMPLETED